ASX Announcements

Name: Amplia Therapeutics
Address: Level 29, 55 Collins Street, Melbourne, VIC, 3000, Australia

16 Apr 2024	Proposed issue of securities - ATX

16 Apr 2024	Entitlement Offer Cleansing Statement

16 Apr 2024	Rights Issue Investor Slide Deck

16 Apr 2024	Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27

12 Apr 2024	Trading Halt

10 Apr 2024	AACR Conference Presentation

27 Mar 2024	Update on ACCENT Trial in Pancreatic Cancer
	KAZ3y-I4wNk

30 Jan 2024	Quarterly Activities/Appendix 4C Cash Flow Report

18 Jan 2024	FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
	OZFWlTCU5ys

17 Jan 2024	Amplia Reports First Patient Dosing In Phase 2a Accent Trial

02 Jan 2024	Change of Director's Interest Notice - Dr Warwick Tong

02 Jan 2024	Change of Director's Interest Notice - Dr Chris Burns

02 Jan 2024	Change of Director's Interest Notice - Dr Robert Peach

02 Jan 2024	Change of Director's Interest Notice - Jane Bell

02 Jan 2024	Notification of cessation of securities - ATX

02 Jan 2024	Application for quotation of securities - ATX

04 Dec 2023	Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea

21 Nov 2023	Appendix 4D and Financial Report Half Year ended 30 Sep 23

31 Oct 2023	Quarterly Activities/Appendix 4C Cash Flow Report

30 Oct 2023	Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer

19 Oct 2023	Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million

09 Oct 2023	AACR Ovarian Cancer Conference Presentation

29 Sep 2023	AACR Pancreatic Cancer Conference Presentation

25 Sep 2023	New Chief Financial Officer Mr Tim Luscombe

04 Sep 2023	Notification of cessation of securities - ATX

01 Sep 2023	Notification of cessation of securities - ATX

01 Sep 2023	Change of Director's Interest Notice - Dr Robert Peach

29 Aug 2023	Change of Director's Interest Notice - Dr Christopher Burns

29 Aug 2023	Notification regarding unquoted securities - ATX

24 Aug 2023	Results of Annual General Meeting

24 Aug 2023	CEO and MD Presentation to Annual General Meeting

02 Aug 2023	ACCENT Trial Recruitment Update

31 Jul 2023	ATX Quarterly Activities and Cashflow Reports - June 23 Qtr

21 Jul 2023	Notice of Annual General Meeting/Proxy Form

20 Jul 2023	ATX - Shareholder Newsletter July 2023

12 Jul 2023	Application for quotation of securities - ATX

21 Jun 2023	AMP945 International Nonproprietary Name Narmafotinib

19 Jun 2023	Amplia AGM to be held Thursday 24 August 2023

31 May 2023	Key to Corporate Governance Disclosures

30 May 2023	2023 Corporate Governance Statement

30 May 2023	Annual Report to Shareholders

29 May 2023	AMP945 and FOLFIRINOX active in model of Pancreatic Cancer

23 May 2023	Grant to collaborate with CSIRO Supplementary Announcement

22 May 2023	Amplia receives grant to collaborate with CSIRO

09 May 2023	ACCENT Trial Recruitment Progress

26 Apr 2023	Quarterly Activities and Cashflow Reports - March 23 Qtr

19 Apr 2023	First Patient Recruited to Cohort 3 of ACCENT Trial

11 Apr 2023	Dose Escalation Approved in ACCENT Clinical Trial of AMP945

28 Feb 2023	ACCENT Trial Recruitment Progress

23 Feb 2023	ATX - US Conference Presentation

09 Feb 2023	AmpliaTherapeutics - Lorne Cancer Conference Presentation

01 Feb 2023	First Patient Recruited to Cohort 2 of Accent Trial

30 Jan 2023	Quarterly Activities and Cashflow Reports - December 2022

11 Jan 2023	Dose Escalation Approved in ACCENT Clinical Trial of AMP945

20 Dec 2022	Letter to Shareholders End of Year Summary and 2023 Plans

01 Dec 2022	Final Director's Interest Notice - Dr. John Lambert

29 Nov 2022	ACCENT Trial Recruitment Progress

18 Nov 2022	Appendix 4D and Financial Report Half Year ended 30 Sep 22

07 Nov 2022	Amplia Appoints Dr Christopher Burns CEO & Managing Director

28 Oct 2022	Quarterly Activities and Cashflow Reports - Sep 2022 Qtr

10 Oct 2022	Notification regarding unquoted securities - ATX

03 Oct 2022	AMP886 Activity in Acute Myeloid Leukemia

14 Sep 2022	AACR Conference Presentation

12 Sep 2022	CEO Resignation

07 Sep 2022	Notification regarding unquoted securities - ATX

07 Sep 2022	Change of Director's Interest Notice - Dr. Warwick Tong

07 Sep 2022	Change of Director's Interest Notice - Dr. Robert Peach

07 Sep 2022	Change of Director's Interest Notice - Dr. Christopher Burns

07 Sep 2022	Change of Director's Interest Notice - Mrs. Jane Bell

06 Sep 2022	Change of Director's Interest Notice - Dr. John Lambert

02 Sep 2022	Notification of cessation of securities - ATX

31 Aug 2022	Amplia Receives $1.8m R&D Tax Incentive

25 Aug 2022	Results of Annual General Meeting

25 Aug 2022	CEO & Managing Director Presentation to AGM

17 Aug 2022	Annual General Meeting - ESOP and New Constitution

17 Aug 2022	Employee Security Ownership Plan

04 Aug 2022	Change of Director's Interest Notice - Dr. Warwick Tong

02 Aug 2022	First Patient Recruited to ACCENT Trial in Pancreatic Cancer

28 Jul 2022	Quarterly Activities and Cashflow Reports - June 2022 Qtr

25 Jul 2022	Presentation at Major Pancreatic Cancer Conference

22 Jul 2022	Notice of Annual General Meeting/Proxy - YE 31 March 2022

07 Jul 2022	Change of Director's Interest Notice - Dr. Chistopher Burns

07 Jul 2022	Change of Director's Interest Notice - Dr. Robert Peach

07 Jul 2022	Change of Director's Interest Notice - Dr. John Lambert

07 Jul 2022	Change of Director's Interest Notice - Dr. Warwick Tong

05 Jul 2022	Notification of cessation of securities - ATX

30 Jun 2022	Application for quotation of securities - ATX

29 Jun 2022	Annual General Meeting to be held Thursday 25 August 2022

24 Jun 2022	Registered Office and Principal Place of Business

09 Jun 2022	Notification of Expiry of Unlisted Options

09 Jun 2022	Application for quotation of securities - ATX

02 Jun 2022	AMP945 Shows Efficacy in Model of Lung Fibrosis

30 May 2022	App 4G - Key to Corporate Governance Disclosures

30 May 2022	Corporate Governance Statement

30 May 2022	Preliminary Final Report and Annual Report YE 31 March 2022

13 May 2022	Amplia Receives Second Ethics Clearance for Phase 2 Trial

12 May 2022	Amplia Presentation to 16th Bioshares Biotech Summit

09 May 2022	AMP945 Pre-IND Meeting Outcome

19 Apr 2022	Quarterly Activities and Cashflow Reports - March 2022 Qtr

06 Apr 2022	Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients

05 Apr 2022	Notification of cessation of securities - ATX

17 Feb 2022	AMP945 Improves Survival in Human Pancreatic Cancer Model

15 Feb 2022	ATX Abstract accepted for presentation at Cancer Conference

14 Feb 2022	Sale of Unmarketable Parcels of Shares

10 Feb 2022	Change of Director's Interest Notice - Jane Bell

01 Feb 2022	Amplia Investor Presentation - February 2022

24 Jan 2022	Quarterly Activities and Cashflow Reports - Dec 2021 Qtr

19 Jan 2022	Notification regarding unquoted securities - ATX

13 Jan 2022	Amplia Completes Manufacture of AMP945 for Planned Trials

22 Dec 2021	Application for quotation of securities - ATX

22 Dec 2021	Application for quotation of securities - ATX

21 Dec 2021	App 3Y - Change of Director's Interest - Mrs Jane Bell

21 Dec 2021	App 3Y - Change of Director's Interest - Dr. Chris Burns

21 Dec 2021	App 3Y - Change of Director's Interest - Dr. Robert Peach

21 Dec 2021	App 3Y - Change of Director's Interest - Dr. John Lambert

21 Dec 2021	App 3Y - Change of Directors Interest Notice - Dr. W. Tong

21 Dec 2021	Proposed issue of securities - ATX

20 Dec 2021	Update - Application for quotation of securities - ATX

17 Dec 2021	Results of Extraordinary General Meeting

16 Dec 2021	Amplia Provides Updated Investor Presentation

15 Dec 2021	Update - Application for quotation of securities - ATX

14 Dec 2021	Update - Proposed issue of securities - ATX

10 Dec 2021	Entitlement Offer Completed

02 Dec 2021	Amplia Awarded $2.1M R&D Cash Flow Loan

24 Nov 2021	App 4D and Financial Report Half Year ended 30 Sep 2021

19 Nov 2021	Notice of Extraordinary General Meeting - 17 Dec 2021

18 Nov 2021	Summary Results - Successful Phase 1 Clinical Trial AMP945

17 Nov 2021	Inhibition of FAK by AMP945 in Phase 1 Clinical Trial

16 Nov 2021	Becoming a Substantial Holder - Acorn Capital Limited

15 Nov 2021	Application for quotation of securities - ATX

15 Nov 2021	Change in substantial holding

15 Nov 2021	Application for quotation of securities - ATX

12 Nov 2021	Section 708A Cleansing Notice - Share Placement

12 Nov 2021	Blueflag Holding - Change of Interest of Substantial Holder

12 Nov 2021	Application for quotation of securities - ATX

08 Nov 2021	Proposed issue of securities - ATX

08 Nov 2021	Proposed issue of securities - ATX

08 Nov 2021	Capital Raising Investor Presentation

08 Nov 2021	Entitlement Offer Prospectus

08 Nov 2021	Placement and Underwritten Entitlement Offer to Raise $12.4m

04 Nov 2021	Amplia and CRUK agree to Amend Licence Terms - AMP886

04 Nov 2021	Trading Halt

27 Oct 2021	Quarterly Activities and Cashflow Reports - Sep 2021 Qtr

26 Oct 2021	Amplia Appoints New Oncology Clinical Advisor

19 Oct 2021	Amplia Provides Updated Investor Presentation

14 Oct 2021	Amplia Receives $1.1m R&D Tax Incentive

01 Oct 2021	Amplia Appoints New Chief Financial Officer

30 Sep 2021	New Garvan Publication Supports Amplia Phase 2 Design

28 Sep 2021	Proactive Investors Lifesciences Webinar Presentation

27 Sep 2021	Amplia to Present at Proactive Investor Lifesciences Webinar

15 Sep 2021	Phase 2 Trial in First-Line Pancreatic Cancer Patients

15 Sep 2021	Updated Investor Presentation

06 Sep 2021	Change of Director's Interest Notice - Jane Bell

27 Aug 2021	Results of Annual General Meeting

27 Aug 2021	AGM - Chief Executive Officer's Presentation

20 Aug 2021	Annual General Meeting Arrangements

28 Jul 2021	Quarterly Activities and Cashflow Reports and Presentation

26 Jul 2021	Shareholder Update and Presentation

23 Jul 2021	App 4G - Key to Corporate Governance Disclosures

23 Jul 2021	2021 Corporate Governance Statement

23 Jul 2021	Annual Report to Shareholders - YE 31 March 2021

23 Jul 2021	Notice of Annual General Meeting/Proxy Form

21 Jul 2021	Results from Successful Phase 1 Clinical Trial of AMP945

29 Jun 2021	Financial Report YE 31 March 2021 - Audited

28 Jun 2021	Amplia and Garvan Enter Into Collaboration Agreement

25 Jun 2021	Annual General Meeting to be Held 27 August 2021

08 Jun 2021	Change of Director's Interest - Dr. Lambert Exercise Options

07 Jun 2021	Application for quotation of securities - ATX

07 Jun 2021	Application for quotation of securities - ATX

02 Jun 2021	AMP945 Improves Survival in Pancreatic Cancer Model

01 Jun 2021	Application for Quotation of Shares - Options Exercised

31 May 2021	App 4E - Preliminary Final Report YE 31 March 2021

11 May 2021	Change in substantial holding

10 May 2021	Section 708A Cleansing Notice - Share Placement

10 May 2021	Appendix 2A - Application for Quotation of Shares

10 May 2021	Appendix 3G - Notification of Issue of Securties - Options

04 May 2021	Proposed issue of Securities - ATX

04 May 2021	Amplia Announces $3.8m Share Placement

30 Apr 2021	Trading Halt

28 Apr 2021	Preclinical Data Support Development AMP945 Pancreatic Cancer

28 Apr 2021	Quarterly Report and Shareholder Update

22 Apr 2021	Initial Director's Interest Notice - Jane Bell

22 Apr 2021	Shareholder Update and Presentation

20 Apr 2021	ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH

15 Apr 2021	Amplia Completes Dosing in Phase 1 Clinical Study of AMP945

12 Apr 2021	Amplia Appoints New Non-Executive Director

25 Mar 2021	Change of Registered Office and Principal Place of Business

24 Mar 2021	Appendix 2A - Exercise of Options

18 Mar 2021	Amplia and Garvan Institute Enter Collaboration Agreement

17 Mar 2021	Amplia Completes Single Dose Study of AMP945

17 Feb 2021	Amplia Initiates Multiple Dose Study of AMP945

16 Feb 2021	Appendix 2A - Exercise of Options

11 Feb 2021	Investor Update - February 2021

28 Jan 2021	Quarterly Activities and Cashflow Reports - Dec 2020 Qtr

11 Jan 2021	Appendix 2A - Exercise of Options

17 Dec 2020	Shareholder Update - 2020 Review

02 Dec 2020	Amplia Receives $0.53m R&D Tax Incentive

27 Nov 2020	Appendix 4D and Financial Report Half Year Ended 30 Sep 2020

24 Nov 2020	Appendix 2A - Allot Shares upon Exercise of Options

02 Nov 2020	Notice ASX LR 3.11.2 - Change of Exercise Price of Options

29 Oct 2020	ATX - Sep 2020 Quarter Activities and Cashflow Reports

21 Oct 2020	Amplia Presentation to Reach Market Services - Meet the CEO

20 Oct 2020	Response to ASX Price Query

08 Oct 2020	First Human Dose in Phase 1 Clinical Trial of AMP945

18 Sep 2020	Change of Director's Interest Notice - Dr. Warwick Tong

18 Sep 2020	Change of Director's Interest Notice - Dr. Robert Peach

18 Sep 2020	Change of Director's Interest Notice - Dr. C. Burns

18 Sep 2020	Section 708A Cleansing Notice - Allotment of Shares

18 Sep 2020	Appendix 2A - Application for Quotation of Shares

18 Sep 2020	Results of Annual General Meeting

18 Sep 2020	CEO Presentation to AGM

08 Sep 2020	Amplia Receives Ethics Clearance to Conduct Phase 1 Trial

02 Sep 2020	Appendix 3G - Notification of Issue of Securities - Options

31 Aug 2020	Amplia Appoints Dr Mark Devlin as Chief Scientific Officer

17 Aug 2020	Notice of Annual General Meeting & Proxy - YE 31 March 2020

06 Aug 2020	Change in Substantial Holding - Blueflag Holdings Pty Ltd

06 Aug 2020	Change in Substantial Holding - Platinum Investment Management Limited

05 Aug 2020	Change of Director Interest - Dr Lambert - Entitlement Offer

05 Aug 2020	Change of Directors Interest - Dr W Tong - Entitlement Offer

04 Aug 2020	Appendix 2A - Retail Entitlement Offer

31 Jul 2020	Appendix 4G - Key to Corporate Governance Disclosures

31 Jul 2020	2020 Corporate Governance Statement

31 Jul 2020	Annual Report to Shareholders - YE 31 March 2020

30 Jul 2020	Entitlement Offer Completed

27 Jul 2020	Quarterly Activities and Cashflow Reports - June 2020

23 Jul 2020	Nucleus Network Appointed to Conduct Phase 1 Clinical Trial

20 Jul 2020	AGM to be held Friday 18 September 2020

14 Jul 2020	Change of Director's Interest Notice - Dr. Warwick Tong

14 Jul 2020	Becoming a substantial holder

14 Jul 2020	Becoming a substantial holder

14 Jul 2020	Change in substantial holding

10 Jul 2020	Appendix 2A - Institutional Entitlement Offer

08 Jul 2020	Entitlement Offer - Despatch of Retail Offer Booklet

03 Jul 2020	Institutional Entitlement Offer Completed

01 Jul 2020	Appendix 3B - Rights Issue

01 Jul 2020	Entitlement Offer Cleansing Notice

01 Jul 2020	Capital Raising - Investor Presentation

01 Jul 2020	Entitlement Offer to Fund Phase 1 Clinical Trial

30 Jun 2020	Preclinical Toxicology Studies Support Phase1 Clinical Trial

29 Jun 2020	Trading Halt

25 Jun 2020	Full Year Statutory Accounts - YE 31 March 2020

02 Jun 2020	Investor Presentation

29 May 2020	Preliminary Final Report - YE 31 March 2020

19 May 2020	FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis

28 Apr 2020	Quarterly Activities Report - March 2020 Qtr

28 Apr 2020	App 4C - Quarterly Cash Flow Report - March 2020 Qtr

07 Apr 2020	Shares to be Released from Voluntary Escrow

25 Mar 2020	FDA Awards Orphan Drug Designation for Pancreatic Cancer

13 Feb 2020	Professor Paul Timpson Joins Amplia's SAB

12 Feb 2020	Initial Director's Interest Notice - John Lambert

07 Feb 2020	Final Director's Interest Notice - Behrenbruch

07 Feb 2020	Final Director's Interest Notice - Wilkinson

07 Feb 2020	Final Director's Interest Notice - Cooke

06 Feb 2020	Dr. John Lambert appointed as Managing Director

06 Feb 2020	Board Restructuring

30 Jan 2020	Placement Cleasing Statement

30 Jan 2020	Appendix 4C Cash Flow - Dec 2019 Qtr

28 Jan 2020	Ceasing to be a substantial holder - Behrenbruch

28 Jan 2020	Becoming a substantial holder

24 Jan 2020	Appendix 3B - Placement

20 Jan 2020	Amplia Therapeutics Undertakes Placement

16 Jan 2020	Trading Halt

18 Dec 2019	Change of Registered Office and Principal Place of Business

17 Dec 2019	Shareholder Update / 2019 Review

29 Nov 2019	App 4D - Financial Report Half Year Ended 30 Sep 2019

01 Nov 2019	App 4C - Sep 2019 Qtr Cash Flows Statement

17 Sep 2019	Change of Director's Interest - Dr Robert Peach - Placement

17 Sep 2019	Change of Director's Interest - Dr C Behrenbruch - Placement

17 Sep 2019	Change of Director's Interest - Dr Warwick Tong, Placement

17 Sep 2019	Placement Cleansing Notice

17 Sep 2019	App 3B Placement Shares and Options to Directors and Mgt

02 Sep 2019	Amplia Therapeutics Provides Manufacturing Update

30 Aug 2019	Results of Annual General Meeting

21 Aug 2019	Change of Director's Interest - S Wilkinson - Options Lapsed

12 Aug 2019	Amplia Therapeutics - Quarterly Update

05 Aug 2019	Change of Director's Interest - Dr Warwick Tong Rights Issue

05 Aug 2019	Change of Director's Interest - Dr Chris Burns, Rights Issue

05 Aug 2019	Change of Director's Interest - Andrew Cooke, Rights Issue

31 Jul 2019	Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr

31 Jul 2019	RightsIssue Participation Supports Clinical-Enabling Studies

25 Jul 2019	Amplia Therapeutics - Bioshares Presentation July 2019

25 Jul 2019	Appendix 4G - Key to Corporate Governance Disclosures

25 Jul 2019	2019 Corporate Governance Statement

25 Jul 2019	Notice of Annual General Meeting/Proxy Form

25 Jul 2019	Annual Report to Shareholders - YE 31 March 2019

23 Jul 2019	Amplia Therapeutics Reports Lead Candidate Preclinical Data

22 Jul 2019	Amplia to present to Bioshares Biotech Summit

09 Jul 2019	Update - July 2019 Newsletter

01 Jul 2019	Letter to Shareholders - Rights Issue

28 Jun 2019	Appendix 3B - Rights Issue

28 Jun 2019	Rights Issue Prospectus

27 Jun 2019	Financial Report Year Ended 31 March 2019

24 Jun 2019	Dr John Lambert appointed as new CEO

17 Jun 2019	Preliminary Rights Issue Details

14 Jun 2019	Placement Cleansing Notice

14 Jun 2019	Appendix 3B - Placement $360k

12 Jun 2019	Capital Raising for Clinical-Enabling Studies

29 May 2019	Preliminary Final Report - Year Ended 31 March 2019

30 Apr 2019	Appendix 4C - Quarterly Statement of Cash Flows

01 Apr 2019	European Patent Completes IP Protection in Major Markets

11 Mar 2019	Amplia Expands Advisory Board

12 Feb 2019	Update - February 2019 Newsletter

29 Nov 2018	App 4D Half Year Accounts 30 Sep 2018

13 Nov 2018	Change of Director's Interest - Wilkinson - Options Expired

07 Nov 2018	Change of Director's Interest Notice - Andrew Cooke

30 Oct 2018	Appendix 4C - quarterly

05 Sep 2018	Amplia Investor Introduction

05 Sep 2018	Change of Name to Amplia Therapeutics Limited - ATX

04 Sep 2018	Change of Director's Interest - Cooke - Options

04 Sep 2018	Change of Director's Interest - Peach - Options

04 Sep 2018	Change of Director's Interest - Wilkinson - Options

04 Sep 2018	Appendix 3B - Options

ASX Announcements

Quick Links

Contact Us

Email Alerts